Unfolding the genetic basis of pemphigus

Abstract

References1 Theut Riis P, Pedersen OB, Sigsgaard V et al. Prevalence of patients with self-reported hidradenitis suppurativa in a cohort of Danish blood donors: a cross-sectional study. Br J Dermatol 2019; 180:774-81. 2 Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol 2015; 73:S4-7. 3 Revuz JE, Canoui-Poitrine F, Wolkenstein P et al. Prevalence and factors associated with hidradenitis suppurativa: results from two casecontrol studies. J Am Acad Dermatol 2008; 59:596-601. 4 Grant A, Gonzalez T, Montgomery MO et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind placebo controlled crossover trial. J Am Acad Dermatol 2010; 62:205-17. 5 Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161:831-9. 6 Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35:191-4. 7 Cosmatos I, Matcho A, Weinstein R et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2017; 68:412-19. 8 Shalom G, Babaev M, Freud T et al. Demographic and health care service utilization by 4417 patients with hidradenitis suppurativa. J Am Acad Dermatol 2017; 77:e2.